| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_32c3e246e15b21c5a93ea35625a68235
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0f20fc6fb5ce9cce4cd06823a0a47cff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_38125833372b4c692e9d0a5bc6302432
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6b8040ff1a47e862cff433484d549c70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bb932b20844c08d22f6d6ecc17159f57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_52c812e974c4b2dc5231ee6556739eac |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70546 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56966
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6881 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2012-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2016-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_43d613b76878454dedaea821ba5dbee0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_937b6ad06d13769a67d4573d906bbaec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60a89faaed30c67246fbc5cd5b5c0927
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eec03ebd90595ed040aa4f5c21f51371
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_23114e799457f51465caaecd55cf7039 |
| publicationDate |
2016-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9328386-B2 |
| titleOfInvention |
Markers for susceptibility to an inhibitor of an Src-family kinase |
| abstract |
The present invention relates to a method for predicting the responsiveness of a mammalian tumor cell or cancer cell to an inhibitor of a kinase of the Src family, such as dasatinib, bosutinib, saracatinib or ponatinib. The present invention also provides for a method for predicting the responsiveness of an individual to an inhibitor of a kinase of the Src family, whereby the individual is suspected to suffer from cancer. These methods involve the evaluation of the status of integrin β4, wherein said status is indicative for the responsiveness to the inhibitor. Furthermore, a kit useful for carrying out the methods described herein as well as an oligo—or polynucleotide and/or antibodies capable of detecting the expression level of integrin β4 for predicting the responsiveness to the inhibitor are provided. |
| priorityDate |
2011-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |